Clinical trial
Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma
NCT00042497 · Anosys, Industry · Suspended
Key facts
| NCT number | NCT00042497 |
|---|---|
| Title | Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma |
| Official title | A Phase II, Multicenter, Open-Labeled Study of Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma |
| Lead sponsor | Anosys, Industry |
| Status | Suspended |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Biological |
| Interventions | autologous dexosomes loaded with tumor-specific peptides |
| Enrollment | 60 |
| Start date | Jul 1, 2002 |
| First posted | Aug 1, 2002 |
| Last update posted | Jun 24, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: